Portfolio of Big Pharma and Biotech Cancer Immunotherapy Stocks
Here are 9 big pharma and big biotech cancer immunotherapy stocks.
| 9 Big Pharma and Biotech Cancer Immunotherapy Stocks | ||
|---|---|---|
Name | Symbol | Recent Prices |
| Amgen | AMGN | |
| AstraZeneca | AZN | |
| Bristol-Myers Squibb | BMY | |
| Gilead Sciences | GILD | |
| Incyte Corporation | INCY | |
| Merck | MRK | |
| Nektar Therapeutics | NKTR | |
| Novartis | NVS | |
| Pfizer | PFE | |
| Sparkline weekly price charts based on Alpha Vantage data. | ||
| 9 Big Pharma and Biotech Cancer Immunotherapy Stocks | ||
|---|---|---|
Name | Symbol | Last Close |
| Amgen | AMGN | $230.44 |
| AstraZeneca | AZN | $55.55 |
| Bristol-Myers Squibb | BMY | $70.53 |
| Gilead Sciences | GILD | $62.32 |
| Incyte Corporation | INCY | $68.83 |
| Merck | MRK | $87.55 |
| Nektar Therapeutics | NKTR | $3.14 |
| Novartis | NVS | $76.67 |
| Pfizer | PFE | $44.14 |
Portfolio Values
To inspect the performance of the Big Pharma and Biotech Cancer Immunotherapy Stocks portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Alpha Vantage.All 9 stocks are included in the portfolio computations. The current value of the portfolio assumes that $1,111.11 was invested in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends.The current value of the $10,000 investment is $12,362. The percent return is 23.62%. The annualized return is 4.33%.
| 9 Big Pharma and Biotech Cancer Immunotherapy Stocks Returns | ||
|---|---|---|
Name | Symbol | Monthly Returns & Details |
| Amgen | AMGN | 52.36% |
| AstraZeneca | AZN | 87.21% |
| Bristol-Myers Squibb | BMY | 32.33% |
| Gilead Sciences | GILD | 1.00% |
| Incyte Corporation | INCY | -39.22% |
| Merck | MRK | 94.94% |
| Nektar Therapeutics | NKTR | -86.97% |
| Novartis | NVS | 11.59% |
| Pfizer | PFE | 59.34% |
Portfolio Value Chart for Last 100 Daily Closes